ESMO Voice of China First-line cetuximab combined chemotherapy applied to the real-world retrospective analysis of colorectal cancer patients in China

The 2022 Annual Meeting of the European Society of Oncology (ESMO) was held

As first-line treatment based on cetuximab has become the standard treatment for RAS wild-type metastatic colon cancer (mCRC), how do real-world data for this regimen perform? At this annual meeting, Professor Chen Zhoucheng of Taichung Veterans General Hospital in Taiwan, China, published a real-world retrospective analysis to evaluate the efficacy of first-line cetuximab combined with chemotherapy

Cetuximab plus chemotherapy has been approved as a first-line treatment for

The researchers collected data from patients with RAS wild-type mCRC who received first-line cetuximab plus chemotherapy in 13 hospitals in Taiwan province from November 2016 to August 2020, and analyzed the baseline characteristics, treatment status and survival benefits of patients

The study was analysed based on 698 eligible patient profiles with a median age of 61.

The data showed that the objective response rate (ORR) and disease control rate (DCR) of all patients were 62.

After a median follow-up of 22.
5 months, the median overall survival (OS) and median progression-free survival (PFS) were 34.
6 months and 14.
7 months, respectively, as shown in
Figure 1.

Figure 1 OS and PFS performance of all patients

A stratified analysis based on tumor location showed that for patients with RAS wild-type mCRC, the median OS performance of patients with left tumors was significantly better than that of patients with right tumors (36.
3 months vs.
19.
7 months, p<0.
001), and the median PFS of the two groups was 14.
9 months and 11.
7 months (p=0.
173), respectively, as shown in
Figure 2.

Figure 2 OS versus PFS in patients with tumors on the left and patients on the right

In addition, patients undergoing metastatic tumor resection experienced significant improvement in their median OS (53.
2 vs.
29.
0 months, p<0.
001
).

For patients who did not undergo metastatic tumor resection, the median OS performance in patients with left tumors was similarly better than in patients with right tumors (29.
8 months vs 16.
7 months, p<0.
001).

However, for patients undergoing metastatic tumor resection, the median OS of patients with left and right tumors was 54.
3 months and 52.
3 months (p=0.
329), respectively, and median PFS was 21.
7 months and 31.
1 months (p=0.
312), respectively, with no significant difference (Figure 3).

Figure 3 OS versus PFS in patients with left tumor resection versus patients on the right

As shown in Table 1, most adverse events (AEs) were grade 1-2, with the most common grade 3-4 adverse events being neutropenia (6.
4%) and skin reactions (3.
2%)
.

Table 1 Security analysis

This real-world analysis shows that first-line cetuximab combined chemotherapy has good efficacy and manageable
safety in patients with RAS wild-type Chinese mCRC.

Metastasectomy can significantly improve the patient's OS
during or after first-line cetuximab plus chemotherapy, regardless of whether the tumor is on the left or right side.

References:

1.
 C-C.
Chen, et al.
Real-world evidence of efficacy and safety in first-line cetuximab treatment of RAS wild-type metastatic colorectal cancer: A multicenter retrospective study in Taiwan.
 406P 2022 ESMO Congress.

Edit: Traveller

Typography: Wanderer

Execution: Traveller